| 1 | role | 36,718 |
| 2 | roles | 3,605 |
| 3 | co-factor | 31 |
| 4 | prolyse | 5 |
| 5 | discoverer | 4 |
| 6 | effecter | 4 |
| 7 | 'statistics | 3 |
| 8 | alterity | 3 |
| 9 | key-role | 3 |
| 10 | radioactivities | 3 |
| 11 | 'pill | 2 |
| 12 | betaseron/betaferon | 2 |
| 13 | derivants | 2 |
| 14 | drug-of-choice | 2 |
| 15 | gerosuppressor | 2 |
| 16 | igbomina-ekiti | 2 |
| 17 | introduction/increase | 2 |
| 18 | invecchiare | 2 |
| 19 | mainstreams | 2 |
| 20 | non-homogeneity | 2 |
| 21 | ortho-quinones | 2 |
| 22 | pbpi | 2 |
| 23 | prerequirement | 2 |
| 24 | quinoxaline-di-n-oxide-derivative | 2 |
| 25 | redox-state | 2 |
| 26 | storehouse | 2 |
| 27 | triazolo-benzodiazepines | 2 |
| 28 | usefullness | 2 |
| 29 | vagaries | 2 |
| 30 | 'ghosts | 1 |
| 31 | 'lab | 1 |
| 32 | 'man | 1 |
| 33 | 'script | 1 |
| 34 | -evidence-base | 1 |
| 35 | 1-benzyl-2-phenyl-group | 1 |
| 36 | 115.0° | 1 |
| 37 | 125i-fibrinogen-uptake-test | 1 |
| 38 | 13-th | 1 |
| 39 | 17-substituents | 1 |
| 40 | 1:1,420 | 1 |
| 41 | 3,4-pyridynes | 1 |
| 42 | 3-aminopropamide | 1 |
| 43 | 3-arylquinolines | 1 |
| 44 | 5mrs | 1 |
| 45 | 6,045 | 1 |
| 46 | abl-values | 1 |
| 47 | active-cream | 1 |
| 48 | activity/efficacy | 1 |
| 49 | aduras | 1 |
| 50 | allocator | 1 |
| 51 | althelets | 1 |
| 52 | aluy | 1 |
| 53 | anatomo-pathologist | 1 |
| 54 | applicaiton | 1 |
| 55 | authors/clinicians | 1 |
| 56 | autoinducers | 1 |
| 57 | avert-study | 1 |
| 58 | azaarene-substituted | 1 |
| 59 | b600 | 1 |
| 60 | badhs | 1 |
| 61 | bc-loop | 1 |
| 62 | bdiq | 1 |
| 63 | benefice/harms | 1 |
| 64 | beta-group | 1 |
| 65 | bioanode | 1 |
| 66 | biovariations | 1 |
| 67 | bmj,11 | 1 |
| 68 | body-sway | 1 |
| 69 | bottle-neck | 1 |
| 70 | bra- | 1 |
| 71 | c-atoms | 1 |
| 72 | candesartin | 1 |
| 73 | chanrades | 1 |
| 74 | chargers | 1 |
| 75 | chemoautotrophs | 1 |
| 76 | cholesterol-level | 1 |
| 77 | churacteristics | 1 |
| 78 | citadel | 1 |
| 79 | coadjuvants | 1 |
| 80 | commons'-emerges | 1 |
| 81 | d/dangiotens | 1 |
| 82 | defict | 1 |
| 83 | degradation/metabolism | 1 |
| 84 | di0/rc | 1 |
| 85 | differencies | 1 |
| 86 | dissension | 1 |
| 87 | dm-treatment | 1 |
| 88 | dna-intercalators | 1 |
| 89 | dom-project | 1 |
| 90 | drawstring | 1 |
| 91 | dreiländertreffen | 1 |
| 92 | drivers'efficacy | 1 |
| 93 | enedial | 1 |
| 94 | enzyme-entrapment | 1 |
| 95 | epididymistail | 1 |
| 96 | etconhc6f5 | 1 |
| 97 | exacerbants | 1 |
| 98 | exposome | 1 |
| 99 | faws | 1 |
| 100 | fev1/fev | 1 |
| 101 | fibresigmoidoscope | 1 |
| 102 | finapres-technique | 1 |
| 103 | friedrich-loeffler-institute | 1 |
| 104 | glucose-responsiveness | 1 |
| 105 | glycosomes | 1 |
| 106 | guthrie-test | 1 |
| 107 | h-transport | 1 |
| 108 | hands/feet/nails | 1 |
| 109 | hdl-cholesterol-increase | 1 |
| 110 | hegemonikon | 1 |
| 111 | hemi-fields | 1 |
| 112 | hg-concentration | 1 |
| 113 | hochrhein-institute | 1 |
| 114 | horsefly | 1 |
| 115 | hpa-response | 1 |
| 116 | hpl-concentration | 1 |
| 117 | hr-pathway | 1 |
| 118 | igbos | 1 |
| 119 | imidazole-ketones | 1 |
| 120 | immunodynamics | 1 |
| 121 | immunohistochemistry/fluorescence | 1 |
| 122 | inconsistences | 1 |
| 123 | indole-3-substituted | 1 |
| 124 | injuries.women | 1 |
| 125 | innohep | 1 |
| 126 | intervention-as-implemented | 1 |
| 127 | intraratio | 1 |
| 128 | isoko | 1 |
| 129 | jas-gl | 1 |
| 130 | laser-patterns | 1 |
| 131 | leitmotif | 1 |
| 132 | li-vacancy | 1 |
| 133 | limb/lever | 1 |
| 134 | liver.and | 1 |
| 135 | llmis | 1 |
| 136 | lower-third | 1 |
| 137 | luminescencies | 1 |
| 138 | lunatum | 1 |
| 139 | machairodontinae | 1 |
| 140 | mainproblem | 1 |
| 141 | man-midwife | 1 |
| 142 | mbfs | 1 |
| 143 | metalloproteome | 1 |
| 144 | metaplasy | 1 |
| 145 | metastasis-inhibitor | 1 |
| 146 | mg-vacancy | 1 |
| 147 | micrease | 1 |
| 148 | microfluidically | 1 |
| 149 | microperfusate | 1 |
| 150 | mono-products | 1 |
| 151 | morning/tgm | 1 |
| 152 | non-normality/outliers | 1 |
| 153 | non-reactants | 1 |
| 154 | nsks | 1 |
| 155 | ogbaru | 1 |
| 156 | oncomir | 1 |
| 157 | oscolations | 1 |
| 158 | p-diastereomers | 1 |
| 159 | passions | 1 |
| 160 | patients'shoulders | 1 |
| 161 | pavilionhospital | 1 |
| 162 | phenylthio-moiety | 1 |
| 163 | phosphatids | 1 |
| 164 | protocol-13 | 1 |
| 165 | psychiatric-disorders | 1 |
| 166 | puff-ball | 1 |
| 167 | ralationship | 1 |
| 168 | researcher/clinician | 1 |
| 169 | roal | 1 |
| 170 | rocker-soled | 1 |
| 171 | saftey | 1 |
| 172 | sagnal | 1 |
| 173 | secoyohimbanes | 1 |
| 174 | sentries | 1 |
| 175 | shif | 1 |
| 176 | shipibo-conibo | 1 |
| 177 | ssdr | 1 |
| 178 | st-values | 1 |
| 179 | sti-prevalence | 1 |
| 180 | stress-increment | 1 |
| 181 | study-9 | 1 |
| 182 | syst-chin | 1 |
| 183 | thoraxcentre | 1 |
| 184 | threonine-47 | 1 |
| 185 | thyrocyte | 1 |
| 186 | time-changes | 1 |
| 187 | tinzapararin | 1 |
| 188 | tlfs | 1 |
| 189 | tq-segment | 1 |
| 190 | tsabfs | 1 |
| 191 | tumorogenicity | 1 |
| 192 | university-centre | 1 |
| 193 | upper-maroni | 1 |
| 194 | urino-culture | 1 |
| 195 | usa.4 | 1 |
| 196 | vinylborate | 1 |
| 197 | watchwords | 1 |
| 198 | weaknessess | 1 |
| 199 | wtt2 | 1 |
| 200 | ye'kuana | 1 |
| 201 | β3-subunit | 1 |
| 202 | δcd | 1 |
| 1 | 'ghosts | 1 |
| 2 | 'lab | 1 |
| 3 | 'man | 1 |
| 4 | 'pill | 2 |
| 5 | 'script | 1 |
| 6 | 'statistics | 3 |
| 7 | -evidence-base | 1 |
| 8 | 1-benzyl-2-phenyl-group | 1 |
| 9 | 115.0° | 1 |
| 10 | 125i-fibrinogen-uptake-test | 1 |
| 11 | 13-th | 1 |
| 12 | 17-substituents | 1 |
| 13 | 1:1,420 | 1 |
| 14 | 3,4-pyridynes | 1 |
| 15 | 3-aminopropamide | 1 |
| 16 | 3-arylquinolines | 1 |
| 17 | 5mrs | 1 |
| 18 | 6,045 | 1 |
| 19 | abl-values | 1 |
| 20 | active-cream | 1 |
| 21 | activity/efficacy | 1 |
| 22 | aduras | 1 |
| 23 | allocator | 1 |
| 24 | alterity | 3 |
| 25 | althelets | 1 |
| 26 | aluy | 1 |
| 27 | anatomo-pathologist | 1 |
| 28 | applicaiton | 1 |
| 29 | authors/clinicians | 1 |
| 30 | autoinducers | 1 |
| 31 | avert-study | 1 |
| 32 | azaarene-substituted | 1 |
| 33 | b600 | 1 |
| 34 | badhs | 1 |
| 35 | bc-loop | 1 |
| 36 | bdiq | 1 |
| 37 | benefice/harms | 1 |
| 38 | beta-group | 1 |
| 39 | betaseron/betaferon | 2 |
| 40 | bioanode | 1 |
| 41 | biovariations | 1 |
| 42 | bmj,11 | 1 |
| 43 | body-sway | 1 |
| 44 | bottle-neck | 1 |
| 45 | bra- | 1 |
| 46 | c-atoms | 1 |
| 47 | candesartin | 1 |
| 48 | chanrades | 1 |
| 49 | chargers | 1 |
| 50 | chemoautotrophs | 1 |
| 51 | cholesterol-level | 1 |
| 52 | churacteristics | 1 |
| 53 | citadel | 1 |
| 54 | co-factor | 31 |
| 55 | coadjuvants | 1 |
| 56 | commons'-emerges | 1 |
| 57 | d/dangiotens | 1 |
| 58 | defict | 1 |
| 59 | degradation/metabolism | 1 |
| 60 | derivants | 2 |
| 61 | di0/rc | 1 |
| 62 | differencies | 1 |
| 63 | discoverer | 4 |
| 64 | dissension | 1 |
| 65 | dm-treatment | 1 |
| 66 | dna-intercalators | 1 |
| 67 | dom-project | 1 |
| 68 | drawstring | 1 |
| 69 | dreiländertreffen | 1 |
| 70 | drivers'efficacy | 1 |
| 71 | drug-of-choice | 2 |
| 72 | effecter | 4 |
| 73 | enedial | 1 |
| 74 | enzyme-entrapment | 1 |
| 75 | epididymistail | 1 |
| 76 | etconhc6f5 | 1 |
| 77 | exacerbants | 1 |
| 78 | exposome | 1 |
| 79 | faws | 1 |
| 80 | fev1/fev | 1 |
| 81 | fibresigmoidoscope | 1 |
| 82 | finapres-technique | 1 |
| 83 | friedrich-loeffler-institute | 1 |
| 84 | gerosuppressor | 2 |
| 85 | glucose-responsiveness | 1 |
| 86 | glycosomes | 1 |
| 87 | guthrie-test | 1 |
| 88 | h-transport | 1 |
| 89 | hands/feet/nails | 1 |
| 90 | hdl-cholesterol-increase | 1 |
| 91 | hegemonikon | 1 |
| 92 | hemi-fields | 1 |
| 93 | hg-concentration | 1 |
| 94 | hochrhein-institute | 1 |
| 95 | horsefly | 1 |
| 96 | hpa-response | 1 |
| 97 | hpl-concentration | 1 |
| 98 | hr-pathway | 1 |
| 99 | igbomina-ekiti | 2 |
| 100 | igbos | 1 |
| 101 | imidazole-ketones | 1 |
| 102 | immunodynamics | 1 |
| 103 | immunohistochemistry/fluorescence | 1 |
| 104 | inconsistences | 1 |
| 105 | indole-3-substituted | 1 |
| 106 | injuries.women | 1 |
| 107 | innohep | 1 |
| 108 | intervention-as-implemented | 1 |
| 109 | intraratio | 1 |
| 110 | introduction/increase | 2 |
| 111 | invecchiare | 2 |
| 112 | isoko | 1 |
| 113 | jas-gl | 1 |
| 114 | key-role | 3 |
| 115 | laser-patterns | 1 |
| 116 | leitmotif | 1 |
| 117 | li-vacancy | 1 |
| 118 | limb/lever | 1 |
| 119 | liver.and | 1 |
| 120 | llmis | 1 |
| 121 | lower-third | 1 |
| 122 | luminescencies | 1 |
| 123 | lunatum | 1 |
| 124 | machairodontinae | 1 |
| 125 | mainproblem | 1 |
| 126 | mainstreams | 2 |
| 127 | man-midwife | 1 |
| 128 | mbfs | 1 |
| 129 | metalloproteome | 1 |
| 130 | metaplasy | 1 |
| 131 | metastasis-inhibitor | 1 |
| 132 | mg-vacancy | 1 |
| 133 | micrease | 1 |
| 134 | microfluidically | 1 |
| 135 | microperfusate | 1 |
| 136 | mono-products | 1 |
| 137 | morning/tgm | 1 |
| 138 | non-homogeneity | 2 |
| 139 | non-normality/outliers | 1 |
| 140 | non-reactants | 1 |
| 141 | nsks | 1 |
| 142 | ogbaru | 1 |
| 143 | oncomir | 1 |
| 144 | ortho-quinones | 2 |
| 145 | oscolations | 1 |
| 146 | p-diastereomers | 1 |
| 147 | passions | 1 |
| 148 | patients'shoulders | 1 |
| 149 | pavilionhospital | 1 |
| 150 | pbpi | 2 |
| 151 | phenylthio-moiety | 1 |
| 152 | phosphatids | 1 |
| 153 | prerequirement | 2 |
| 154 | prolyse | 5 |
| 155 | protocol-13 | 1 |
| 156 | psychiatric-disorders | 1 |
| 157 | puff-ball | 1 |
| 158 | quinoxaline-di-n-oxide-derivative | 2 |
| 159 | radioactivities | 3 |
| 160 | ralationship | 1 |
| 161 | redox-state | 2 |
| 162 | researcher/clinician | 1 |
| 163 | roal | 1 |
| 164 | rocker-soled | 1 |
| 165 | role | 36,718 |
| 166 | roles | 3,605 |
| 167 | saftey | 1 |
| 168 | sagnal | 1 |
| 169 | secoyohimbanes | 1 |
| 170 | sentries | 1 |
| 171 | shif | 1 |
| 172 | shipibo-conibo | 1 |
| 173 | ssdr | 1 |
| 174 | st-values | 1 |
| 175 | sti-prevalence | 1 |
| 176 | storehouse | 2 |
| 177 | stress-increment | 1 |
| 178 | study-9 | 1 |
| 179 | syst-chin | 1 |
| 180 | thoraxcentre | 1 |
| 181 | threonine-47 | 1 |
| 182 | thyrocyte | 1 |
| 183 | time-changes | 1 |
| 184 | tinzapararin | 1 |
| 185 | tlfs | 1 |
| 186 | tq-segment | 1 |
| 187 | triazolo-benzodiazepines | 2 |
| 188 | tsabfs | 1 |
| 189 | tumorogenicity | 1 |
| 190 | university-centre | 1 |
| 191 | upper-maroni | 1 |
| 192 | urino-culture | 1 |
| 193 | usa.4 | 1 |
| 194 | usefullness | 2 |
| 195 | vagaries | 2 |
| 196 | vinylborate | 1 |
| 197 | watchwords | 1 |
| 198 | weaknessess | 1 |
| 199 | wtt2 | 1 |
| 200 | ye'kuana | 1 |
| 201 | β3-subunit | 1 |
| 202 | δcd | 1 |
| 1 | bra- | 1 |
| 2 | b600 | 1 |
| 3 | 1:1,420 | 1 |
| 4 | bmj,11 | 1 |
| 5 | wtt2 | 1 |
| 6 | protocol-13 | 1 |
| 7 | usa.4 | 1 |
| 8 | 6,045 | 1 |
| 9 | etconhc6f5 | 1 |
| 10 | threonine-47 | 1 |
| 11 | study-9 | 1 |
| 12 | ye'kuana | 1 |
| 13 | 'lab | 1 |
| 14 | di0/rc | 1 |
| 15 | δcd | 1 |
| 16 | rocker-soled | 1 |
| 17 | intervention-as-implemented | 1 |
| 18 | indole-3-substituted | 1 |
| 19 | azaarene-substituted | 1 |
| 20 | liver.and | 1 |
| 21 | lower-third | 1 |
| 22 | machairodontinae | 1 |
| 23 | drug-of-choice | 2 |
| 24 | immunohistochemistry/fluorescence | 1 |
| 25 | sti-prevalence | 1 |
| 26 | 3-aminopropamide | 1 |
| 27 | bioanode | 1 |
| 28 | man-midwife | 1 |
| 29 | role | 36,718 |
| 30 | key-role | 3 |
| 31 | metalloproteome | 1 |
| 32 | exposome | 1 |
| 33 | fibresigmoidoscope | 1 |
| 34 | invecchiare | 2 |
| 35 | university-centre | 1 |
| 36 | thoraxcentre | 1 |
| 37 | urino-culture | 1 |
| 38 | -evidence-base | 1 |
| 39 | micrease | 1 |
| 40 | hdl-cholesterol-increase | 1 |
| 41 | introduction/increase | 2 |
| 42 | hpa-response | 1 |
| 43 | storehouse | 2 |
| 44 | prolyse | 5 |
| 45 | vinylborate | 1 |
| 46 | microperfusate | 1 |
| 47 | redox-state | 2 |
| 48 | hochrhein-institute | 1 |
| 49 | friedrich-loeffler-institute | 1 |
| 50 | thyrocyte | 1 |
| 51 | finapres-technique | 1 |
| 52 | quinoxaline-di-n-oxide-derivative | 2 |
| 53 | shif | 1 |
| 54 | leitmotif | 1 |
| 55 | drawstring | 1 |
| 56 | 13-th | 1 |
| 57 | upper-maroni | 1 |
| 58 | pbpi | 2 |
| 59 | igbomina-ekiti | 2 |
| 60 | bottle-neck | 1 |
| 61 | enedial | 1 |
| 62 | sagnal | 1 |
| 63 | roal | 1 |
| 64 | pavilionhospital | 1 |
| 65 | citadel | 1 |
| 66 | cholesterol-level | 1 |
| 67 | jas-gl | 1 |
| 68 | epididymistail | 1 |
| 69 | puff-ball | 1 |
| 70 | 'pill | 2 |
| 71 | active-cream | 1 |
| 72 | mainproblem | 1 |
| 73 | morning/tgm | 1 |
| 74 | degradation/metabolism | 1 |
| 75 | lunatum | 1 |
| 76 | researcher/clinician | 1 |
| 77 | 'man | 1 |
| 78 | dreiländertreffen | 1 |
| 79 | injuries.women | 1 |
| 80 | syst-chin | 1 |
| 81 | tinzapararin | 1 |
| 82 | candesartin | 1 |
| 83 | dissension | 1 |
| 84 | hg-concentration | 1 |
| 85 | hpl-concentration | 1 |
| 86 | hegemonikon | 1 |
| 87 | betaseron/betaferon | 2 |
| 88 | applicaiton | 1 |
| 89 | shipibo-conibo | 1 |
| 90 | intraratio | 1 |
| 91 | isoko | 1 |
| 92 | innohep | 1 |
| 93 | ralationship | 1 |
| 94 | bc-loop | 1 |
| 95 | beta-group | 1 |
| 96 | 1-benzyl-2-phenyl-group | 1 |
| 97 | bdiq | 1 |
| 98 | ssdr | 1 |
| 99 | discoverer | 4 |
| 100 | effecter | 4 |
| 101 | limb/lever | 1 |
| 102 | oncomir | 1 |
| 103 | gerosuppressor | 2 |
| 104 | allocator | 1 |
| 105 | co-factor | 31 |
| 106 | metastasis-inhibitor | 1 |
| 107 | aduras | 1 |
| 108 | immunodynamics | 1 |
| 109 | churacteristics | 1 |
| 110 | 'statistics | 3 |
| 111 | phosphatids | 1 |
| 112 | hemi-fields | 1 |
| 113 | watchwords | 1 |
| 114 | inconsistences | 1 |
| 115 | chanrades | 1 |
| 116 | time-changes | 1 |
| 117 | commons'-emerges | 1 |
| 118 | luminescencies | 1 |
| 119 | differencies | 1 |
| 120 | vagaries | 2 |
| 121 | sentries | 1 |
| 122 | radioactivities | 3 |
| 123 | roles | 3,605 |
| 124 | glycosomes | 1 |
| 125 | secoyohimbanes | 1 |
| 126 | 3-arylquinolines | 1 |
| 127 | triazolo-benzodiazepines | 2 |
| 128 | ortho-quinones | 2 |
| 129 | imidazole-ketones | 1 |
| 130 | 3,4-pyridynes | 1 |
| 131 | abl-values | 1 |
| 132 | st-values | 1 |
| 133 | tsabfs | 1 |
| 134 | mbfs | 1 |
| 135 | tlfs | 1 |
| 136 | badhs | 1 |
| 137 | chemoautotrophs | 1 |
| 138 | llmis | 1 |
| 139 | nsks | 1 |
| 140 | hands/feet/nails | 1 |
| 141 | mainstreams | 2 |
| 142 | c-atoms | 1 |
| 143 | benefice/harms | 1 |
| 144 | authors/clinicians | 1 |
| 145 | d/dangiotens | 1 |
| 146 | passions | 1 |
| 147 | biovariations | 1 |
| 148 | oscolations | 1 |
| 149 | laser-patterns | 1 |
| 150 | igbos | 1 |
| 151 | autoinducers | 1 |
| 152 | patients'shoulders | 1 |
| 153 | psychiatric-disorders | 1 |
| 154 | chargers | 1 |
| 155 | non-normality/outliers | 1 |
| 156 | p-diastereomers | 1 |
| 157 | 5mrs | 1 |
| 158 | dna-intercalators | 1 |
| 159 | glucose-responsiveness | 1 |
| 160 | usefullness | 2 |
| 161 | weaknessess | 1 |
| 162 | mono-products | 1 |
| 163 | althelets | 1 |
| 164 | exacerbants | 1 |
| 165 | non-reactants | 1 |
| 166 | derivants | 2 |
| 167 | coadjuvants | 1 |
| 168 | 17-substituents | 1 |
| 169 | 'ghosts | 1 |
| 170 | faws | 1 |
| 171 | dom-project | 1 |
| 172 | defict | 1 |
| 173 | β3-subunit | 1 |
| 174 | stress-increment | 1 |
| 175 | prerequirement | 2 |
| 176 | tq-segment | 1 |
| 177 | enzyme-entrapment | 1 |
| 178 | dm-treatment | 1 |
| 179 | 'script | 1 |
| 180 | h-transport | 1 |
| 181 | guthrie-test | 1 |
| 182 | 125i-fibrinogen-uptake-test | 1 |
| 183 | anatomo-pathologist | 1 |
| 184 | ogbaru | 1 |
| 185 | fev1/fev | 1 |
| 186 | hr-pathway | 1 |
| 187 | body-sway | 1 |
| 188 | drivers'efficacy | 1 |
| 189 | activity/efficacy | 1 |
| 190 | mg-vacancy | 1 |
| 191 | li-vacancy | 1 |
| 192 | avert-study | 1 |
| 193 | saftey | 1 |
| 194 | horsefly | 1 |
| 195 | microfluidically | 1 |
| 196 | metaplasy | 1 |
| 197 | phenylthio-moiety | 1 |
| 198 | tumorogenicity | 1 |
| 199 | non-homogeneity | 2 |
| 200 | alterity | 3 |
| 201 | aluy | 1 |
| 202 | 115.0° | 1 |